News & Updates

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
10 Feb 2023 byRoshini Claire Anthony

Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
10 Feb 2023
Does molnupiravir improve outcomes in vaccinated COVID-19 patients?
Does molnupiravir improve outcomes in vaccinated COVID-19 patients?
03 Feb 2023
Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?
03 Feb 2023